The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective cohort study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men, conducted in Baltimore, Chicago, Pittsburgh and Los Angeles (17 (link)). Initial enrollment in the MACS parent study occurred in 1984–85, with additional enrollment in 1987–1991 and 2001–2003. The cohort includes both HIV-infected and uninfected men who attend semiannual research visits including standardized interviews, physical examinations and blood and urine collection for laboratory measurements.
Eligibility for this MACS cardiovascular ancillary study included being an active MACS participant (with oversampling of HIV-infected men), age 40–70 years, weight< 300 lbs, and no prior history of cardiac surgery or percutaneous coronary intervention, as these procedures would interfere with the measurement of coronary atherosclerosis. All participants completed non-contrast cardiac CT scanning for coronary artery calcium (CAC) scoring between January 2010 and August 2013. Men with atrial fibrillation, chronic kidney disease [estimated glomerular filtration rate (GFR)<60 ml/min/m2 during a prior MACS study visit] or a history of IV contrast allergy were excluded from CTA studies. All eligible CTA participants had an estimated GFR>60 ml/min/m2 within one month of CTA. The study was approved by the Institutional Review Boards of all participating sites. All participants signed informed consent for this MACS ancillary study.
Eligibility for this MACS cardiovascular ancillary study included being an active MACS participant (with oversampling of HIV-infected men), age 40–70 years, weight< 300 lbs, and no prior history of cardiac surgery or percutaneous coronary intervention, as these procedures would interfere with the measurement of coronary atherosclerosis. All participants completed non-contrast cardiac CT scanning for coronary artery calcium (CAC) scoring between January 2010 and August 2013. Men with atrial fibrillation, chronic kidney disease [estimated glomerular filtration rate (GFR)<60 ml/min/m2 during a prior MACS study visit] or a history of IV contrast allergy were excluded from CTA studies. All eligible CTA participants had an estimated GFR>60 ml/min/m2 within one month of CTA. The study was approved by the Institutional Review Boards of all participating sites. All participants signed informed consent for this MACS ancillary study.